Regulatory Story

RNS Number : 7256B
Shield Therapeutics PLC
24 September 2018
 

Shield Therapeutics plc

("Shield" or the "Company")

 

PDMR Acquisition of Shares

 

London, UK, 24 September 2018, Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that Carl Sterritt, Chief Executive Officer of the Company, has acquired 88,235 Ordinary Shares in the Company on 21 September 2018 for consideration of £0.34 per Ordinary Share. Following the transaction, Mr Sterritt holds 10,163,496 shares, representing 8.73 % of the Company's issued share capital.

 

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

  

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

Name

 

Carl Sterritt                       

 

2

Reason for the notification

 

a)

Position/status

 

CEO and Director of Shield Therapeutics plc

b)

Initial notification/ Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

 

Shield Therapeutics plc

b)

LEI

 

213800G74QWY15FC3W71

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument

 

 

 

 

 

Identification code

 

Ordinary shares of 1.5p each in the capital of the Company

 

 

 

 

 

 

 

 

 

ISIN of Ordinary Shares: GB00BYV81293

b)

Nature of the transaction

 

Acquisition of Ordinary Shares

c)

Price(s) and volume(s)

 

£0.34 per Ordinary Share

 

Volumes: 88,235

 

d)

Aggregated information

 

-Aggregated volume

 

-Price

 

 

 

 

 

88,235

 

£30,000

e)

Date of the transaction

 

21 September 2018

f)

Place of the transaction

 

London Stock Exchange, AIM Market

 

- Ends -

 

For further information please contact:

 

Shield Therapeutics plc                                                                                                   +44 (0)207 186 8500

Carl Sterritt, Chief Executive Officer

Tim Watts, Interim Chief Financial Officer

 

Nominated Advisor and Joint Broker                                                                        +44 (0)203 100 2222

Liberum Capital Limited

Christopher Britton/Steve Pearce

 

Joint Broker                                                                                                                          +44 (0)207 418 8900

Peel Hunt LLP

James Steel/Dr Christopher Golden

 

 

About Feraccru®

Feraccru® is a novel, stable, non-salt, oral formulation of ferric iron, which has a differentiated mechanism of action compared to salt-based oral iron therapies. When salt-based oral iron therapies are ingested, the iron must dissociate from the salt in the GI tract to allow the iron to be absorbed and treat the IDA.  This free iron readily chelates to form insoluble clumps and produces damaging free radicals that together cause a range of mild-to-severe GI adverse events, including nausea, bloating and constipation, leading to poor tolerability, reduced patient compliance and ultimately treatment failure.  In addition, many patients with IDA are concurrently treated with medicines that raise the pH in the gut which further reduces the effect of salt-based oral iron therapies as they require highly acidic conditions to be absorbed. Feraccru® is not an iron salt, and iron can be absorbed from the ferric maltol molecule, and as a result, it does not routinely cause the same treatment-limiting intolerance issues. Feraccru® has been shown in clinical trials to be well-tolerated by patients even when they had previously failed treatment with salt-based oral iron therapies, which should lead to increased patient compliance and better patient outcomes.

 

Currently, the only treatment option for IDA patients who cannot tolerate salt-based oral iron therapies, is IV iron therapy. IV iron therapies quickly increase iron stores via direct administration of very large doses of iron, causing an increase in Hb levels that is physiologically controlled and occurs over a period of weeks, as is the case with Feraccru®.  IV iron therapies, however, are invasive, costly, inconvenient and complex to administer, and also come with potentially life-threatening, spontaneous hypersensitivity reactions. 

 

Feraccru® has been approved by the European Commission for the treatment of iron deficiency in adults, with or without anaemia.

 

 

About Shield Therapeutics plc

Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.  Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adult patients with or without anaemia. Feraccru® has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com. 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHLZLFLVKFBBBZ